{"resourceType": "Group", "meta": {"versionId": "3", "lastUpdated": "2023-11-30T22:46:19.612Z", "profile": "https://hl7.org/fhir/uv/ebm/StructureDefinition/comparator-definition"}, "id": "179785", "identifier": [{"type": {"text": "FEvIR Object Identifier", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "ACSN", "display": "Accession ID"}]}, "system": "https://fevir.net", "value": "179785", "assigner": {"display": "Computable Publishing LLC"}}], "extension": [{"url": "http://hl7.org/fhir/StructureDefinition/artifact-relatedArtifact", "valueRelatedArtifact": {"type": "cite-as", "citation": "ComparatorDefinition: Usual-care pharmacologic thromboprophylaxis [Group]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 179785. Revised 2023-11-30. Available at: https://fevir.net/resources/Group/179785. Computable resource at: https://fevir.net/resources/Group/179785."}}, {"url": "http://hl7.org/fhir/StructureDefinition/artifact-title", "valueString": "ComparatorDefinition: Usual-care pharmacologic thromboprophylaxis"}, {"url": "http://hl7.org/fhir/StructureDefinition/artifact-url", "valueUri": "https://fevir.net/resources/Group/179785"}, {"url": "http://hl7.org/fhir/StructureDefinition/artifact-publisher", "valueString": "Computable Publishing LLC"}, {"url": "http://hl7.org/fhir/StructureDefinition/artifact-copyright", "valueMarkdown": "https://creativecommons.org/licenses/by-nc-sa/4.0/"}, {"url": "http://hl7.org/fhir/StructureDefinition/artifact-contact", "valueContactDetail": {"telecom": [{"system": "email", "value": "support@computablepublishing.com"}]}}, {"url": "http://hl7.org/fhir/StructureDefinition/artifact-author", "valueContactDetail": {"name": "Brian S. Alper"}}, {"url": "https://hl7.org/fhir/uv/ebm/StructureDefinition/combination-method", "valueCode": "any-of"}], "membership": "definitional", "characteristic": [{"code": {"text": "Defined by CodeableConcept"}, "valueCodeableConcept": {"text": "Standard venous thromboprophylaxis according to local guidelines or usual practice. Dose of chosen agent should not be more than half of the approved therapeutic dose for the treatment of venous thromboembolism."}, "exclude": false, "extension": [{"url": "https://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-description", "valueMarkdown": "ATTACC comparator arm"}, {"extension": [{"url": "contextCode", "valueCodeableConcept": {"text": "Start of trial"}}, {"url": "offset", "valueRange": {"low": {"value": 0}, "high": {"value": 14, "unit": "days", "system": "http://unitsofmeasure.org", "code": "d"}}}, {"url": "text", "valueString": "Up to 14 days or until hospital discharge, whichever comes first. After this period, decisions regarding thromboprophylaxis are at discretion of treating clinician."}], "url": "https://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-timing"}]}, {"code": {"text": "Defined by CodeableConcept"}, "valueCodeableConcept": {"text": "Any one of enoxaparin, dalteparin, tinzaparin, fondaparinux, or heparin according to local preference. Dose of agent specified to be consistent with guidelines for low dose thromboprophylaxis."}, "exclude": false, "extension": [{"url": "https://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-description", "valueMarkdown": "ACTIV-4a comparator arm"}, {"extension": [{"url": "contextCode", "valueCodeableConcept": {"text": "Start of trial"}}, {"url": "offset", "valueRange": {"low": {"value": 0}, "high": {"value": 14, "unit": "days", "system": "http://unitsofmeasure.org", "code": "d"}}}, {"url": "text", "valueString": "Up to 14 days or until hospital discharge, whichever comes first. After this period, decisions regarding thromboprophylaxis are at discretion of treating clinician."}], "url": "https://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-timing"}]}, {"code": {"text": "Defined by CodeableConcept"}, "valueCodeableConcept": {"text": "Standard venous thromboprophylaxis according to local guidelines or usual practice. Dose of chosen agent should not be sufficient to result in therapeutic anticoagulation."}, "exclude": false, "extension": [{"url": "https://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-description", "valueMarkdown": "REMAP-CAP comparator arm"}, {"extension": [{"url": "contextCode", "valueCodeableConcept": {"text": "Start of trial"}}, {"url": "offset", "valueRange": {"low": {"value": 0}, "high": {"value": 14, "unit": "days", "system": "http://unitsofmeasure.org", "code": "d"}}}, {"url": "text", "valueString": "Up to 14 days or until hospital discharge, whichever comes first. After this period, decisions regarding thromboprophylaxis are at discretion of treating clinician."}], "url": "https://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-timing"}]}], "description": "Description: usual-care pharmacologic thromboprophylaxis\nNote: Thromboprophylaxis was provided at a dose and duration determined by the treating clinician according to local practice.\nNote: Usual-care pharmacological thromboprophylaxis included both intermediate-intensity (in 27%) and prophylactic-intensity dosing (in 72%). Subgroup analyses may be informative to determine if there is a difference related to the intensity used in the control arm of the trial.", "modifierExtension": [{"url": "http://hl7.org/fhir/StructureDefinition/artifact-status", "valueCode": "active"}], "type": "animal"}